FOXD3-AS1 suppresses the progression of non-small cell lung cancer by regulating miR-150/SRCIN1axis. 2020

Tao Ji, and Yanan Zhang, and Zheng Wang, and Zuoxu Hou, and Xuhui Gao, and Xiaoming Zhang
Department of Cardiothoracic Surgery, General Hospital of Central Theater Command, Wuhan, Hubei, China.

BACKGROUND Long non-coding RNA (lncNRA) forkhead box D3 antisense RNA 1 (FOXD3-AS1) has been proved to promote or suppress the occurrence and development of multiple types of human tumors. However, the function and mechanism of FOXD3-AS1 in non-small cell lung cancer (NSCLC) are scarcely understood. METHODS qRT-PCR was used for detecting FOXD3-AS1, miR-150 and SRC kinase signaling inhibitor 1 (SRCIN1) mRNA expression in NSCLC tissues, and the relationship between pathological characteristics of NSCLC patients and FOXD3-AS1 expression level was analyzed. With human NSCLC cell lines H1299 and A549 as cell models, CCK-8 and BrdU assays were employed for detecting cancer cell proliferation, and Transwell assay was employed for detecting cell invasion ability. Dual luciferase reporter gene assay and RNA immunoprecipitation (RIP) assay were used for the verification of the targeting relationshipe between FOXD3-AS1 and miR-150, and Western blot was employed for detecting SRCIN1 protein expression. RESULTS FOXD3-AS1 expression was significantly reduced in NSCLC tissues and cell lines, and low expression of FOXD3-AS1 was closely related to positive lymph node metastasis and relatively high tumor grade. FOXD3-AS1 over-expression inhibited the proliferation and invasion of H1299 cell lines, while its knockdown promoted the proliferation and invasion of A549 cells. Additionally, it was confirmed that FOXD3-AS1 suppressed the expression of miR-150 by targeting it, and up-regulated the expression of SRCIN1. CONCLUSIONS FOXD3-AS1 indirectly enhances the expression of SRCIN1 by targeting miR-150, thereby inhibiting NSCLC progression.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011013 Pneumonectomy The excision of lung tissue including partial or total lung lobectomy. Bronchoscopic Lung Volume Reduction,Endoscopic Lung Volume Reduction,Lung Volume Reduction,Lung Volume Reduction Surgery,Partial Pneumonectomy,Partial Pneumonectomies,Pneumonectomies,Pneumonectomy, Partial,Reduction, Lung Volume,Volume Reduction, Lung
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D005260 Female Females

Related Publications

Tao Ji, and Yanan Zhang, and Zheng Wang, and Zuoxu Hou, and Xuhui Gao, and Xiaoming Zhang
December 2021, Oncology letters,
Tao Ji, and Yanan Zhang, and Zheng Wang, and Zuoxu Hou, and Xuhui Gao, and Xiaoming Zhang
March 2020, European review for medical and pharmacological sciences,
Tao Ji, and Yanan Zhang, and Zheng Wang, and Zuoxu Hou, and Xuhui Gao, and Xiaoming Zhang
January 2020, OncoTargets and therapy,
Tao Ji, and Yanan Zhang, and Zheng Wang, and Zuoxu Hou, and Xuhui Gao, and Xiaoming Zhang
April 2020, European review for medical and pharmacological sciences,
Tao Ji, and Yanan Zhang, and Zheng Wang, and Zuoxu Hou, and Xuhui Gao, and Xiaoming Zhang
July 2020, Neoplasma,
Tao Ji, and Yanan Zhang, and Zheng Wang, and Zuoxu Hou, and Xuhui Gao, and Xiaoming Zhang
June 2024, Cellular and molecular biology (Noisy-le-Grand, France),
Tao Ji, and Yanan Zhang, and Zheng Wang, and Zuoxu Hou, and Xuhui Gao, and Xiaoming Zhang
March 2022, Cell journal,
Tao Ji, and Yanan Zhang, and Zheng Wang, and Zuoxu Hou, and Xuhui Gao, and Xiaoming Zhang
November 2020, Pathology, research and practice,
Tao Ji, and Yanan Zhang, and Zheng Wang, and Zuoxu Hou, and Xuhui Gao, and Xiaoming Zhang
March 2020, Thoracic cancer,
Tao Ji, and Yanan Zhang, and Zheng Wang, and Zuoxu Hou, and Xuhui Gao, and Xiaoming Zhang
January 2022, Disease markers,
Copied contents to your clipboard!